- Home
- IMAB vs ONCY Comparison
IMAB vs ONCY Comparison
Compare IMAB & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- ONCY
- Stock Information
- Founded
- IMAB 2014
- ONCY 1998
- Country
- IMAB United States
- ONCY Canada
- Employees
- IMAB N/A
- ONCY N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- ONCY Pharmaceuticals and Biotechnology
- Sector
- IMAB Health Care
- ONCY Health Care
- Exchange
- IMAB Nasdaq
- ONCY Nasdaq
- Market Cap
- IMAB 83.8M
- ONCY 86.1M
- IPO Year
- IMAB 2020
- ONCY 1999
- Fundamental
- Price
- IMAB $0.94
- ONCY $0.77
- Analyst Decision
- IMAB Strong Buy
- ONCY Strong Buy
- Analyst Count
- IMAB 3
- ONCY 2
- Target Price
- IMAB $8.00
- ONCY $4.00
- AVG Volume (30 Days)
- IMAB 288.7K
- ONCY 359.4K
- Earning Date
- IMAB 08-28-2024
- ONCY 11-12-2024
- Dividend Yield
- IMAB N/A
- ONCY N/A
- EPS Growth
- IMAB N/A
- ONCY N/A
- EPS
- IMAB N/A
- ONCY N/A
- Revenue
- IMAB $3,313,984.00
- ONCY N/A
- Revenue This Year
- IMAB N/A
- ONCY N/A
- Revenue Next Year
- IMAB N/A
- ONCY N/A
- P/E Ratio
- IMAB N/A
- ONCY N/A
- Revenue Growth
- IMAB N/A
- ONCY N/A
- 52 Week Low
- IMAB $0.90
- ONCY $0.76
- 52 Week High
- IMAB $2.54
- ONCY $1.53
- Technical
- Relative Strength Index (RSI)
- IMAB 38.29
- ONCY 26.96
- Support Level
- IMAB $0.91
- ONCY $0.91
- Resistance Level
- IMAB $1.11
- ONCY $0.88
- Average True Range (ATR)
- IMAB 0.07
- ONCY 0.04
- MACD
- IMAB -0.00
- ONCY -0.01
- Stochastic Oscillator
- IMAB 13.01
- ONCY 11.12
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About ONCY Oncolytics Biotech Inc.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.